VBS.AU Vectus Biosystems Ltd

Healthcare Biotechnology Australian Securities Exchange
0.0750 AUD
Close of Nov 1, 2026
0.0750 0.4550
Market cap
AUD 4.66M
P/E
2.5x
P/B
2.01x
ROE
67.2%
Dividend yield
-
Fundamental score
2.3/5

Ratios use the latest price and the fiscal year ending Jun 2026.

Is VBS.AU undervalued?

Graham number
Price0.0750
Graham value0.1587
Discount52.7%

VBS.AU trades 52.7% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Vectus Biosystems Ltd fundamental analysis

11 of 22 checks passed

ROE 2/2

High return on equity (67.2%), above 20%.

ROA 1/1

Return on assets (40.8%) is above the industry median (-51.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (184.3%) is above the industry median (-5.3%).

Revenue Growth 0/2

Revenue did not grow over the past 3 years or is not reported.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (23.6%), 40% or less.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Debt Coverage 0/1

Operating cash flow does not cover 20% of total debt.

Interest Coverage 0/1

EBIT is negative, against interest expense, below 5x.

PE vs Market 1/1

PE (2.5x) is below the market median (15.0x).

PE vs Industry 1/1

PE (2.5x) is below the industry median (16.3x).

PBV 1/1

Price to book (2.0x) is below the industry median (4.4x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 5.0, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Vectus Biosystems Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Vectus Biosystems Ltd

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops a pipeline of antifibrotic assets targeting cardiovascular, renal and liver fibrosis to address diseases driven by pathological tissue scarring. Its lead compound is VB0004, currently under phase Ib clinical human trial, which targets the prevention and reversal of fibrosis in the lungs, heart, and kidneys. The company was incorporated in 2005 and is based …

Full company profile